Skip Navigation

European Heart Journal 2000 21(12):958-960; doi:10.1053/euhj.2000.2109
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Weintraub, W.S.
Right arrow Articles by Harrison, D.G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weintraub, W.S.
Right arrow Articles by Harrison, D.G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

C-reactive protein, inflammation and atherosclerosis: do we really understand it yet?

W.S. Weintraub and D.G. Harrison

Division of Cardiology, Emery University, Atlanta, Georgia, U.S.A.

References

  1. Futterman LG, Lemberg L. Inflammation in plaque rupture: an active participant or an invited guest? Am J Crit Care. 1998;7:153–161[Abstract]
  2. Tataru MC, Heinrich J, Junker R. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina. Eur Heart J. 2000;21:1000–1008[Abstract/Free Full Text]
  3. Berk BC, Weintraub WS, Alexander RW. C-reactive protein is elevated in ‘active’ coronary artery disease. Am J Cardiol. 1990;65:168–172[CrossRef][ISI][Medline]
  4. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731–733[Abstract/Free Full Text]
  5. Law M. Lipids and cardiovascular disease. Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ. Evidence based cardiology. London: BMJ Books; 1998. p. 191–205
  6. Yia-Herttuala S, Palinski W, Rosenfeld ME. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086–1095[ISI][Medline]
  7. Krams R, Wentzel JJ, Oomen JAF. Evaluation of endothelial shear stress and 3D geometry as factors determining the development of atherosclerosis and remodeling in human coronary arteries in vivo: Combining 3D reconstruction from angiography and IVUS (ANGUS) with computational fluid dynamics. Arterioscler Thromb Vase Biol. 1997;17:2061–2065
  8. Branzi A, Melandri G, Semprini F. Stable and unstable angina pectoris. Platelets. 1993;4:23–24
  9. Mendall M, Carrington D, Strachan D. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect. 1995;30:121–128[CrossRef][ISI][Medline]
  10. Yla-Herttuala S. Oxidized LDL and atherosclerosis. Ann NY Acad Sci. 1999;874:134–137[Abstract/Free Full Text]
  11. Brightbill HD, Libraty DH, Krutzik SR. Host Defence mechanisms triggered by microbial lipoproteins through toll-like receptors. Science. 1999;285:732–736[Abstract/Free Full Text]
  12. McGuire DK, Granger CB. Diabetes and ischemic heart disease. Am Heart J. 1999;138:S366–S375[CrossRef][ISI][Medline]
  13. U.S. Department of Health and Human Services, Reducing the Health Consequences of Smoking: 25 Years of Progress, (CDC) 89; 8411, 1989
  14. Lonn EM, Yusuf S, Jha P. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90:2056–2069[Free Full Text]
  15. Rajagopalan S, Kurz S, Münzel T. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916–1923[ISI][Medline]
  16. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 1993;73:205–209[Abstract]
  17. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem. 1995;270:319–324[Abstract/Free Full Text]
  18. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153–2157[ISI][Medline]
  19. Lehtimaki T, Lehtinen S, Solakivi T. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol. 1999;19:23–27[Abstract/Free Full Text]
  20. O'Brien KD, Alpers CE, Hokanson JE, Wang S, Chait A. Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein. Circulation. 1996;94:1216–1225[Abstract/Free Full Text]
  21. Otsuki M, Hashimoto K, Morimoto Y, Kishimoto T, Kasayama S. Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients. Diabetes. 1997;46:2096–2101[Abstract]
  22. Pedersen TR. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet. 1994;344:1383–1389[CrossRef][ISI][Medline]
  23. Shepherd J, Cobb SM, Ford I. for the West of Scotland Coronary Prevention study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307[Abstract/Free Full Text]
  24. Downs JR, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–1622[Abstract/Free Full Text]
  25. N Engl J Med. 1998;339:1349–1357[Abstract/Free Full Text]
  26. Sacks FM, Pfefeer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009[Abstract/Free Full Text]
  27. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154–160[Abstract/Free Full Text]
  28. Stephens NG, Parsons A, Schofield PM. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781–786[CrossRef][ISI][Medline]
  29. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153[Abstract/Free Full Text]
  30. Dagenais G. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413–2446[Abstract]
  31. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekends CH. Inflammation, aspirin, and risks of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979[Abstract/Free Full Text]
  32. Lancet. 1988;2:349–360[Medline]
  33. Lancet. 1996;348:1329–1339[CrossRef][ISI][Medline]
  34. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Circulation. 1999;100:230–235[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
A. Akalin, O. Alatas, and O. Colak
Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients
Eur. J. Endocrinol., January 1, 2008; 158(1): 47 - 52.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
X. L. Wang, D. L Rainwater, M. C Mahaney, and R. Stocker
Cosupplementation with vitamin E and coenzyme Q10 reduces circulating markers of inflammation in baboons
Am. J. Clinical Nutrition, September 1, 2004; 80(3): 649 - 655.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. G. Hackam and S. S. Anand
Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidence
JAMA, August 20, 2003; 290(7): 932 - 940.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. C. Pasternak, J. Abrams, P. Greenland, L. A. Smaha, P. W. F. Wilson, and N. Houston-Miller
Task force #1--identification of coronary heart disease risk: is there a detection gap?
J. Am. Coll. Cardiol., June 4, 2003; 41(11): 1863 - 1874.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
I. Kushner and A. R. Sehgal
Is High-Sensitivity C-Reactive Protein an Effective Screening Test for Cardiovascular Risk?
Arch Intern Med, April 22, 2002; 162(8): 867 - 869.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Weintraub, W.S.
Right arrow Articles by Harrison, D.G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weintraub, W.S.
Right arrow Articles by Harrison, D.G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?